Chardan upgraded Kodiak Sciences (KOD) to Buy from Neutral with a $61 price target “Stellar results” from GLOW2, supported by enthusiasm among key opinion leaders with whom the firm spoke to at a recent ARVO conference, confirm the viability of the new formulation of the drug and “erase our doubts about its safety and efficacy profile,” the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KOD: